Seite 2 – CureVac

Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors

1. November 2018Clinical Data,Oncology,Prophylactic Vaccines

mRNA as novel technology for passive immunotherapy

17. Oktober 2018Antibodies,Review Articles

Unifying in vitro and in vivo IVT mRNA expression discrepancies in skeletal muscle via mechanotransduction

1. Oktober 2018Mechanism of Action

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

1. Oktober 2017Mechanism of Action,Natural mRNA,Prophylactic Vaccines,Most Referenced Publications

mRNA mediates passive vaccination against infectious agents, toxins, and tumors

9. August 2017Antibodies,Mechanism of Action,Most Referenced Publications

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial

25. Juli 2017Clinical Data,Prophylactic Vaccines,Most Referenced Publications

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects

11. Januar 2017Mechanism of Action,RNA Immunomodulator,Most Referenced Publications

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response

3. Januar 2017Mechanism of Action,Prophylactic Vaccines

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy

18. November 2016Clinical Data,Oncology

Immunological effects of a novel RNA-based adjuvant in liver cancer patients

10. November 2016Oncology,RNA Immunomodulator